Knockdown of LIMA1 using shRNA reversed the anti-tumor effects of LRP5-overexpressing osteocyte-derived CM, confirming LIMA1’s role as a key downstream effector molecule of the LRP5/Wnt pathway. Here, LRP5 is linked to neoplasm.